Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

NCT00488345 | Completed Phase 2 Results

• 1 other identifier: 3074K4-2207
• Study Type: interventional
• Target: 59
• Locations: 6 countries
• Sites: 36

Brief Summary

To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), or community-acquired pneumonia (CAP).

Conditions

Bacterial Infections; Intra-Abdominal Infection; Pneumonia, Bacterial; Skin Diseases, Bacterial; Skin Diseases, Infectious

Keywords

cIAI; cSSSI; CAP; Child

Outcome Measures

Primary Outcomes (5)

• Maximum Observed Plasma Concentration (Cmax)

  Cmax: tigecycline serum concentration measured in nanograms per milliliter (ng/mL) determined by a validated liquid chromatography with mass spectrophotometric (LC/MS/MS) detection method. Peak concentration was taken directly from the observed data.

  Day 3 (immediately post-dose, 0.75, and 2 hours post-dose)

• Time to Reach Maximum Observed Plasma Concentration (Tmax)

  Time of peak concentration taken directly from the observed data.

  Day 3 (immediately post-dose, 0.75, and 2 hours post-dose)

• Area Under the Curve (AUCτ) From Time Zero to Time of Estimated Concentration at 12 Hours

  AUCτ: AUC between doses from time zero to the time of estimated concentration at 12 hours reported in nanograms \* hours divided by milliliters (ng\*h/mL) was calculated using the log-trapezoidal rule for decreasing concentrations and the linear-trapezoidal rule for increasing concentrations estimating the 12 hour drug concentration if necessary.

  Day 3 (just before and immediately after infusion, and 0.75, 2, and 6 hours post-dose)

• Weight Normalized Drug Clearance (CLW)

  Weight normalized drug clearance measured in liters per hour per kilogram (L/hr/kg). Drug clearance (CL) was determined as the ratio of dose/area under the concentration-time curve from time zero (start of infusion) to 12 hours (start of next infusion) (AUCτ). CLW was determined as the ratio of CL/weight.

  Day 3 (just before and immediately after infusion, and 0.75, 2, and 6 hours post-dose)

• Percentage of Participants With Clinical Response (CR) to Tigecycline at Last Day of Therapy (LDOT) and Test-of-Cure (TOC) Assessment

  CR = Cure: resolution of all signs, symptoms (SS) of infection (INF) or improvement, no further antibacterial therapy (AT) necessary; Improved (IMP): SS IMP to extent that switch to oral AT deemed appropriate; Failure: lack of response, required additional AT, initial recovery then deterioration requiring further AT, death due to the INF after day 2, death due to treatment (TR)-related adverse event (AE), required non-routine surgical TR \>48 hours after 1st dose of TR due to failure to IMP or clinical worsening. TOC = CR, vital signs, physical exam, laboratory results, concomitant TR, and AEs.

  Day 14 or LDOT, TOC Visit (10 to 21 days after last dose of total antibiotic therapy)

Secondary Outcomes (3)

• Population Pharmacokinetic (PK) Model: Volume of Distribution

  3074K4-2207: Day 3 just before and immediately after infusion, and 0.75, 2, and 6 hours post-dose; 3074A1-110: just before and 0.5, 0.75, 1, 2, 3, 4, 8, 12, 24, 36, and 48 hours after start of infusion

• Population Pharmacokinetic (PK) Model: Clearance

  3074K4-2207: Day 3 just before and immediately after infusion, and 0.75, 2, and 6 hours post-dose; 3074A1-110: just before and 0.5, 0.75, 1, 2, 3, 4, 8, 12, 24, 36, and 48 hours after start of infusion

• Population Pharmacokinetic (PK) Model: Effect of Weight

  3074K4-2207: Day 3 just before and immediately after infusion, and 0.75, 2, and 6 hours post-dose; 3074A1-110: just before and 0.5, 0.75, 1, 2, 3, 4, 8, 12, 24, 36, and 48 hours after start of infusion

Study Arms (3)

A

EXPERIMENTAL

0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.

Drug: Tygacil

B

EXPERIMENTAL

1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.

Drug: Tygacil

C

EXPERIMENTAL

1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.

Drug: Tygacil

Interventions

Tygacil DRUG

A; B; C

Eligibility Criteria

• Age: 8 Years - 11 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Male or female patients aged 8 to 11 years, inclusive, willing and able to complete all activities required for the study
• Have a diagnosis of a serious infection (cIAI, cSSSI or CAP) requiring hospitalization and administration of IV antibiotic therapy during greater than or equal to 5 days

You may not qualify if:

• Patients with any concomitant condition or taking any concomitant medication that, in the opinion of the investigator, could preclude an evaluation of safety or efficacy responses or make it unlikely that the anticipated course of therapy or follow-up assessment will be completed (e.g., life expectancy \< 30 days).
• Pregnant or breastfeeding female patients and female patients of childbearing potential who are unable or unwilling to take adequate contraceptive precautions.
• Previous participation in this clinical trial.
• Receipt of any investigational drugs or devices (defined as lacking any regulatory agency's approval within 4 weeks before administration of the first dose of tigecycline).
• Endocarditis; presence of an artificial heart valve or infected device that will not be removed.
• Known or suspected hypersensitivity to tigecycline or other compounds related to this class of antibacterial agents (i.e., tetracyclines).
• Known or suspected P. aeruginosa infection.
• Patients receiving immunosuppressive therapy that, in the opinion of the investigator, would decrease the patient's ability to eradicate the infection, including the use of high-dose corticosteroid.
• Receipt of an organ or bone marrow transplant.
• Presence of any of the following laboratory findings: Neutropenia (absolute neutrophil count \< 1 × 109/L \[\< 1000/mm3\]) , AST or ALT \> 10 × the ULN or bilirubin \> 3 × ULN, unless isolated hyperbilirubinemia is directly related to the acute process (for patients with cIAI).
• Patients with any of the following conditions:
• Cystic fibrosis.
• Active tuberculosis.
• Congenital immunodeficiency.
• Meningitis.

Sponsors & Collaborators

• Wyeth is now a wholly owned subsidiary of Pfizer: lead

Study Sites (36)

Unknown Facility

Long Beach, California, 90806, United States

Location

Unknown Facility

Oakland, California, 94609, United States

Location

Unknown Facility

Orange, California, 92868, United States

Location

Unknown Facility

San Diego, California, 92123, United States

Location

Unknown Facility

Tampa, Florida, 33606, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

Flint, Michigan, 48503, United States

Location

Unknown Facility

Jackson, Mississippi, 39218, United States

Location

Unknown Facility

Omaha, Nebraska, 68131, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

Durham, North Carolina, 27710, United States

Location

Unknown Facility

Akron, Ohio, 44308, United States

Location

Unknown Facility

Cincinnati, Ohio, 45229-3039, United States

Location

Unknown Facility

Hershey, Pennsylvania, 17033-0850, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19104, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15213, United States

Location

Unknown Facility

Salt Lake City, Utah, 84108, United States

Location

Unknown Facility

Richmond, Virginia, 23298, United States

Location

Unknown Facility

Brussels, 1090, Belgium

Location

Unknown Facility

Brussels, 1200, Belgium

Location

Unknown Facility

Guadalarajara Jalisco, 0000, Mexico

Location

Unknown Facility

Parow, 7500, South Africa

Location

Unknown Facility

Pretoria, 0001, South Africa

Location

Unknown Facility

Pretoria, 00082, South Africa

Location

Unknown Facility

Themba, 00040, South Africa

Location

Unknown Facility

Worcester, 6850, South Africa

Location

Unknown Facility

Taipei, Taipei, 100, Taiwan

Location

Unknown Facility

Kyiv, Kyiv Oblast, 4209, Ukraine

Location

Unknown Facility

Lviv, Lviv Oblast, 79085, Ukraine

Location

Unknown Facility

Uzhhorod, Uzhorod, 88000, Ukraine

Location

Unknown Facility

Vinnitsa, Vynnitsa, 21021, Ukraine

Location

Unknown Facility

Dnipropetrovsk, 49100, Ukraine

Location

Unknown Facility

Kharkiv, 61098, Ukraine

Location

Unknown Facility

Kyiv, 0.0405, Ukraine

Location

Unknown Facility

Kyiv, 0.1133, Ukraine

Location

Unknown Facility

Vinnitsa, 21021, Ukraine

Location

Related Publications (1)

• Purdy J, Jouve S, Yan JL, Balter I, Dartois N, Cooper CA, Korth-Bradley J. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther. 2012 Feb;34(2):496-507.e1. doi: 10.1016/j.clinthera.2011.12.010. Epub 2012 Jan 16.

  PMID: 22249106 DERIVED

MeSH Terms

Conditions

Bacterial Infections; Intraabdominal Infections; Pneumonia, Bacterial; Skin Diseases, Bacterial; Skin Diseases, Infectious

Interventions

Tigecycline

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Medical Monitor

  Wyeth is now a wholly owned subsidiary of Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 18, 2007
• First Posted: June 20, 2007
• Study Start: December 1, 2007
• Primary Completion: September 1, 2009
• Study Completion: September 1, 2009
• Last Updated: October 24, 2012
• Results First Posted: October 24, 2012

Record last verified: 2012-09

Locations

ME (1); BE (2); US (18); ZA (5); UA (9); TW (1)